---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

---

 

FORM 8-K

 

---

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):

 

May 24, 2004

 

---

 

Vicuron Pharmaceuticals Inc.

(Exact Name of Registrant As Specified in its Charter)

 

---

 

Delaware		000-31145		04-3278032
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification Nu mber)

 

455 South Gulph Road, Suite 305, King of Prussia, PA 19406

(Address of Principal Executive Offices) (Zip Code)

 

(610) 205-2300

(Registrant’s telephone number, including area code)

 

not applicable

(Former Name or Former Address, if Changed Since Last Report.)

 

---

---

Item 5. Other Events.

 

On May 24, 2004, Vicuron Pharmaceuticals Inc. announced that it received an approvable letter from the U.S. Food and Drug Administration. However, the letter indicated that Vicuron’s New Drug Application submission for anidulafungin does not currently support a labeling claim for the initial treatment of esophageal candidiasis.

 

A copy of the press release relating to such announcement is attached to this Current Report on Form 8-K as Exhibit 99.1

 

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

 

(c) Exhibits.

 

See Exhibit Index attached hereto.

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		VICURON PHARMACEUTICALS INC.
		(Registrant)
Date: May 27, 2004		By:		/s/ George F. Horner III
				George F. Horner III
				President and Chief Executive Officer

 

 

---

EXHIBIT INDEX

 

Pursuant to Item 601(a)(2) of Regulation S-K, this Exhibit Index immediately precedes the exhibit.

 

Exhibit No.		Description
99.1		Press release of Vicuron Pharmaceuticals Inc. dated May 24, 2004.